Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial

Author(s): Toralf Reimer, Ph.D.¹, Angrit Stachs, Ph.D.¹, Kristina Veselinovic, M.D.², Thorsten Kühn, Ph.D.³, Jörg Heil, Ph.D.^4,5 https://orcid.org/0000-0002-4684-9099, Silke Polata, M.D.⁶, Frederik Marmé, Ph.D.⁷, Thomas Müller, Ph.D.⁸, Guido Hildebrandt, Ph.D.⁹, David Krug, Ph.D.^10,11, Beyhan Ataseven, Ph.D.¹², Roland Reitsamer, Ph.D.¹³, Sylvia Ruth, M.D.¹⁴, Carsten Denkert, Ph.D.¹⁵, Inga Bekes, Ph.D.^2,16, Dirk-Michael Zahm, M.D.¹⁷, Marc Thill, Ph.D.¹⁸, Michael Golatta, Ph.D.^4,5, Johannes Holtschmidt, M.D.¹⁹, Michael Knauer, Ph.D.²⁰, Valentina Nekljudova, Ph.D.¹⁹, Sibylle Loibl, Ph.D.¹⁹, and Bernd Gerber, Ph.D.¹

Source: DOI: 10.1056/NEJMoa2412063

Dr. Anjan Patel's Thoughts

The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.

Background

Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear.

Methods

In this prospective, randomized, noninferiority trial, we investigated the omission of axillary surgery as compared with sentinel-lymph-node biopsy in patients with clinically node-negative invasive breast cancer staged as T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo breast-conserving surgery. We report here the per-protocol analysis of invasive disease–free survival (the primary efficacy outcome). To show the noninferiority of the omission of axillary surgery, the 5-year invasive disease–free survival rate had to be at least 85%, and the upper limit of the confidence interval for the hazard ratio for invasive disease or death had to be below 1.271.

Results

A total of 5502 eligible patients (90% with clinical T1 cancer and 79% with pathological T1 cancer) underwent randomization in a 1:4 ratio. The per-protocol population included 4858 patients; 962 were assigned to undergo treatment without axillary surgery (the surgery-omission group), and 3896 to undergo sentinel-lymph-node biopsy (the surgery group). The median follow-up was 73.6 months. The estimated 5-year invasive disease–free survival rate was 91.9% (95% confidence interval [CI], 89.9 to 93.5) among patients in the surgery-omission group and 91.7% (95% CI, 90.8 to 92.6) among patients in the surgery group, with a hazard ratio of 0.91 (95% CI, 0.73 to 1.14), which was below the prespecified noninferiority margin. The analysis of the first primary-outcome events (occurrence or recurrence of invasive disease or death from any cause), which occurred in a total of 525 patients (10.8%), showed apparent differences between the surgery-omission group and the surgery group in the incidence of axillary recurrence (1.0% vs. 0.3%) and death (1.4% vs. 2.4%). The safety analysis indicates that patients in the surgery-omission group had a lower incidence of lymphedema, greater arm mobility, and less pain with movement of the arm or shoulder than patients who underwent sentinel-lymph-node biopsy.

Conclusions

In this trial involving patients with clinically node-negative, T1 or T2 invasive breast cancer (90% with clinical T1 cancer and 79% with pathological T1 cancer), omission of surgical axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years. (Funded by the German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.)

Author Affiliations

¹ Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany; ² University Hospital Ulm, Ulm, Germany; ³ Hospital Esslingen, Esslingen, Germany; ⁴ University Hospital Heidelberg, Heidelberg, Germany; ⁵ Breast Unit, Sankt Elisabeth Hospital, Heidelberg, Germany; ⁶ Evang. Waldkrankenhaus Spandau, Berlin; ⁷ Faculty of Medicine Mannheim, Department of Obstetrics and Gynecology, University of Heidelberg, Mannheim, Germany; ⁸ Department of Obstetrics and Gynecology, Hanau City Hospital, Hanau, Germany; ⁹ Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany; ¹⁰ Department of Radiotherapy and Radiation Oncology, University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany; ¹¹ Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany; ¹² Medical School and University Medical Center OWL, Department of Gynecology and Obstetrics, Bielefeld University, Klinikum Lippe, Detmold, Germany; ¹³ Salzburg Regional Hospital, Salzburg, Austria; ¹⁴ Johanniter Hospital Genthin-Stendal, Stendal, Germany; ¹⁵ Institute of Pathology, Philipps University Marburg and University Hospital Marburg (UKGM), Marburg, Germany; ¹⁶ Breast Center St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland; ¹⁷ SRH Wald-Klinikum Gera, Gera, Germany; ¹⁸ Department of Gynecology and Gynecologic Oncology, Agaplesion Markus Hospital, Frankfurt am Main, Germany; ¹⁹ German Breast Group, Neu-Isenburg, Germany; ²⁰ Tumor and Breast Center Eastern Switzerland, St. Gallen, Switzerland

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

Yet another combination to consider after CDK4/6i + ET in HR+ MBC!

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

TD beat chemotherapy after failure of hormonal therapy in HER-2 low and ultra low. Wait for the indication.